Irene Orlow, MS & PhD

Attending Biologist & Laboratory Member

Share
Print
Share
Print
Irene Orlow, Attending Biologist & Laboratory Member

Office Phone

212-639-3072

Office Fax

212-717-3666

Education

University of Buenos Aires

Current Research Interests/Research Goals

Dr. Orlow directs the Molecular Epidemiology Laboratory. Her research interests include the study of host and tumor genetics, phenotypic characteristics, and exposures that modulate cancer prognosis in patients with skin melanoma, breast, lung and other types of cancer. In the area of melanoma, since the year 2000 she is a member of the international Genes, Environment, and Melanoma (GEM). Study group, and in more recent years of the InterMEL Consortium. Among other efforts in melanoma, studies within GEM include research of genetic variants to help distinguish —at diagnosis— lethal melanoma. She collaborates with members of the Dermatology Service to evaluate the effect of genetics, phenotypic characteristics, and exposures to further the knowledge of the biology and epidemiology of nevi —a known risk factor for melanoma, and the underlying genetic risk factors for chemotherapy-induced persistent alopecia. With Drs. Ahles and Root, she is assessing the impact of genomic and biochemical markers and exposures on neurocognitive function in survivors of breast cancer. With Dr. Mao, she is assessing phenotypic and genetic biomarkers linked to the efficacy of interventions in cancer patients.

With her lab team, Dr. Orlow supports additional multidisciplinary investigations in the areas of cancer etiology, prognosis and survivorship, as well as a study that evaluates genetic determinants of COVID-19 severity. Her laboratory handles biospecimens collections for large epidemiologic studies including, among others, breast, colorectal, pancreatic, endometrial, and bladder cancer, as well as melanoma.

 

Publications

Selected peer-reviewed publications:

  1. Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol, 129(8):1972-1982, 2009. PMC2745834
  2. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, and Orlow I. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol 132:1471-1478, 2012. PMID:22336942
  3. Correa DD, Satagopan J, Baser RE, Cheung K, Richards E, Lin M, Karimi S, Lyo J, DeAngelis LM, Orlow I. Apolipoprotein E polymorphisms and cognitive functions in patients with brain tumors. Neurology 83:320-327, 2014. PMC4115606
  4. Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group. Association of Interferon Regulatory Factor-4polymorphism rs12203592 with divergent melanoma pathways. J Natl Cancer Inst.108(7) 1-9, 2016. PMC4948568
  5. Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, Paine S, Armstrong BK, Kricker A, Marrett LD, Rosso S, Zanetti R, Gruber SB, Anton-Culver H, Gallagher RP, Dwyer T, Busam K, Begg CB, Berwick M; GEM Study Group. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis. 37(1):30-8, 2016. PMC4715233

View a full listing of Irene Orlow’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Irene Orlow discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures